343 related articles for article (PubMed ID: 25342053)
1. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness and safety of natalizumab in a Portuguese population.
Correia I; Batista S; Galego O; Marques IB; Jesus-Ribeiro J; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P
Neurology; 2014 Jul; 83(1):78-86. PubMed ID: 24898925
[TBL] [Abstract][Full Text] [Related]
4. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
5. The toronto observational study of natalizumab in multiple sclerosis.
Krysko KM; O'Connor PW
Can J Neurol Sci; 2011 May; 38(3):422-8. PubMed ID: 21515500
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of fingolimod in a Portuguese real-world population.
Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
8. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
[TBL] [Abstract][Full Text] [Related]
12. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
13. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
[TBL] [Abstract][Full Text] [Related]
15. Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients.
Ribeiro de Barros AH; Fiadeiro Sequeira JP; Lopes de Sousa AS; Cheganças Capela CM; Gomes Pedrosa RM; Dos Santos Manita MA
Clin Neuropharmacol; 2018; 41(4):129-135. PubMed ID: 29927805
[TBL] [Abstract][Full Text] [Related]
16. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
20. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
